TY - JOUR
T1 - Neutralizing Antibody Responses to Reinfecting Strains of Cytomegalovirus in Transplant Recipients
AU - Chou, Sunwen
N1 - Funding Information:
Received for publication 26 October 1988and in revised form 23 January 1989. This work was supported by Veterans Administration research funds. The author thanks Katherine Scott for technical assistance. Please address requests for reprints to Dr. Sunwen Chou, Veterans Administration Medical Center, Infectious Disease Section 11IF, P.O. Box 1034, Portland, OR 97207.
PY - 1989/7
Y1 - 1989/7
N2 - Analysis of cytomegalovirus (CMV) isolates shed by 51 recipients of organs from 24 CMV- seropositive donors was used to assess the relative characteristics of primary infection, reactivation of endogenous virus, and reinfection by a donor CMV strain. Reinfection was more frequent than reactivation of endogenous virus. Symptomatic CMV disease was identified in 21 of 25 primary infections, 2 of 16 reinfections, and 1 of 4 cases of endogenous reactivation. Before receiving a transplant, reinfected recipients had detectable neutralizing antibody to the specific reinfecting strain of CMV and to laboratory strain AD169. Following reinfection, rises in neutralizing antibody titers were observed, comparable to the responses of those with reactivation of endogenous CMV. The preexisting level of neutralizing antibody did not appear to predict clinical outcome, and moderately high levels of neutralizing antibody did not prevent viremia. Thus, posttransplant CMV reinfection occurs frequently and appears clinically, serologically, and virologically similar to reactivation of endogenous virus.
AB - Analysis of cytomegalovirus (CMV) isolates shed by 51 recipients of organs from 24 CMV- seropositive donors was used to assess the relative characteristics of primary infection, reactivation of endogenous virus, and reinfection by a donor CMV strain. Reinfection was more frequent than reactivation of endogenous virus. Symptomatic CMV disease was identified in 21 of 25 primary infections, 2 of 16 reinfections, and 1 of 4 cases of endogenous reactivation. Before receiving a transplant, reinfected recipients had detectable neutralizing antibody to the specific reinfecting strain of CMV and to laboratory strain AD169. Following reinfection, rises in neutralizing antibody titers were observed, comparable to the responses of those with reactivation of endogenous CMV. The preexisting level of neutralizing antibody did not appear to predict clinical outcome, and moderately high levels of neutralizing antibody did not prevent viremia. Thus, posttransplant CMV reinfection occurs frequently and appears clinically, serologically, and virologically similar to reactivation of endogenous virus.
UR - http://www.scopus.com/inward/record.url?scp=0024329023&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024329023&partnerID=8YFLogxK
U2 - 10.1093/infdis/160.1.16
DO - 10.1093/infdis/160.1.16
M3 - Article
C2 - 2543709
AN - SCOPUS:0024329023
SN - 0022-1899
VL - 160
SP - 16
EP - 21
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -